Get the Stockscreener App
318.23
0.11%
-0.34
After Hours:
318.23
Penumbra Inc stock is traded at $318.23, with a volume of 353.53K.
It is down -0.11% in the last 24 hours and down -0.72% over the past month.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
See More
Previous Close:
$318.57
Open:
$318.94
24h Volume:
353.53K
Relative Volume:
0.74
Market Cap:
$12.52B
Revenue:
$1.45B
Net Income/Loss:
$171.05M
P/E Ratio:
73.23
EPS:
4.3459
Net Cash Flow:
$212.73M
1W Performance:
+0.88%
1M Performance:
-0.72%
6M Performance:
+0.40%
1Y Performance:
+26.75%
1-Day Range:
$317.17
$318.94
1-Week Range:
$314.80
$319.19
52-Week Range:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
318.23 | 12.42B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-25 | Initiated | Wells Fargo | Underweight |
| Oct-08-25 | Upgrade | Needham | Hold → Buy |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Penumbra secures European CE mark for Red 72 Silver Label technologies - NeuroNews International
Penumbra, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh - TradingView
REAL Aspiration Catheter from Penumbra Inc.large-vessel stroke workhorse for interventional suite - AD HOC NEWS
PEN Forecast — Price Target — Prediction for 2027 - TradingView
Penumbra Update - TMX Newsfile
Price to book forward of Penumbra, Inc. – HAM:0P8 - TradingView
Enterprise value to EBITDA forward of Penumbra, Inc. – HAM:0P8 - TradingView
Penumbra, Inc. Actuals & Estimates (XETR:0P8) - TradingView
PEN Stock Price Prediction 2025-2026 | Penumbra Inc Forecast - 24/7 Wall St.
Price to sales forward of Penumbra, Inc. – HAM:0P8 - TradingView
Price to earnings forward of Penumbra, Inc. – HAM:0P8 - TradingView
0P8 Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Penumbra, Inc. – NYSE:PEN - TradingView
Enterprise value to EBIT forward of Penumbra, Inc. – NYSE:PEN - TradingView
Form 8K Penumbra Inc For: 22 June By Investing.com - Investing.com South Africa
Penumbra, Inc. 8-K SEC Filing: Key Details, Business Address, NYSE Listing & Shareholder Vote Results - Minichart
Penumbra shareholders elect directors and approve executive pay at annual meeting - Investing.com Nigeria
Penumbra: Portfolio Expands With Approval To Treat Stroke; Acquisition by Boston on Track - Morningstar
Penumbra Expands Portfolio With Approval To Treat Stroke; Acquisition by Boston on Track - Morningstar
Penumbra (PEN) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary - Quartr
Penumbra StockAnalyst and earnings outlook as consensus settles - AD HOC NEWS
(PEN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Penumbra (NYSE:PEN) Medical Device Mid Caps Stay In Focus - Kalkine Media
Microcatheter Market Size to Reach USD 1.79 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain? - TradingView
Why Penumbra Lightning Flash is drawing attention in stroke care - AD HOC NEWS
Penumbra wins CE mark for Thunderbolt clot removal tech - MedTech Dive
Penumbra Inc (PEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Penumbra Inc (PEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Penumbra (PEN) Proxy filing Summary - Quartr
Penumbra Inc (PEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Penumbra Inc (PEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Penumbra Inc (PEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Penumbra Inc (PEN) Institutional Confidence - TradingKey
Penumbra Inc (PEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Penumbra Inc (PEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Penumbra Inc (PEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ursa Fund Management, LLC's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra’s Thunderbolt approval poised to accelerate neuro thrombectomy innovation - Yahoo Finance
VIP Mid Cap Portfolio's Penumbra Inc(PEN) Holding History - GuruFocus
CE Mark Granted to Penumbra's CAVT Platform - dicardiology.com
Penumbra (PEN) Achieves CE Mark for Thunderbolt Technology - GuruFocus
Penumbra expands CAVT for stroke into Europe with Thunderbolt CE mark - NeuroNews International
Penumbra earns CE mark for Thunderbolt thrombectomy system - MassDevice
Penumbra’s Thunderbolt Computer-Assisted Vacuum Thrombectomy Earns CE Mark - Medical Product Outsourcing
Penumbra secures CE Mark for stroke treatment device in Europe By Investing.com - Investing.com South Africa
Penumbra Inc Expands Cavt For Stroke To Europe With CE Mark For Thunderbolt - TradingView
Penumbra secures CE Mark for stroke treatment device in Europe - Investing.com
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT - PR Newswire
Boston Scientific Eyes Neurovascular Growth With Penumbra Thunderbolt Clearance - Yahoo Finance UK
Penumbra CAVT Platform Receives FDA Clearance - dicardiology.com
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.62%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):